QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Family history is a strong factor for developing prostate cancer, as are inherited genetic mutations. A current focus prostate cancer research is identifying which genes are associated with prostate cancer. Identifying these genes would help identify men who are at…
With the increasing adoption of multi-parametric MRI scans that lead to more targeted prostate biopsy procedures, there is increasing consideration by patients and physicians of focal therapy for clinically localized prostate cancer. Focal therapy treats only part of the prostate…
The first descriptive article on Dr. Catalona’s, Witte’s, and Helfand’s SPORE project, “Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort” has been accepted for publication in the Journal of Urology….
Every year, the American Cancer Society publishes an article on their estimates of the numbers of new cancer cases and deaths in the U.S. This year, they reported the latest results that are the incidence rates (newly diagnosed cases) through…
by Betsy Haberl Dr. Stacy Loeb met Dr. William J. Catalona when she was a student at Northwestern University’s Feinberg School of Medicine. Their relationship began as mentor and mentee, but now they are colleagues in the field of medical…
Researchers analyzed 16 studies including more than one million people and found that drinking more coffee was correlated with lower risks of developing prostate cancer. For each additional cup of coffee, there was a nearly 1% decrease in the risk…
Claims that omega-3 fatty acid supplements, including fish oil supplements, are an easy way to reduce the risks of heart disease have spurred their popularity. However, recent research does not support the claim that taking omega-3 supplements is an effective…
by Wayne Lewis Health disparities occur in prostate cancer: risk for the disease is about 75% higher and is more than twice as deadly in Black men compared with white men. Yet white men are often overrepresented as research participants,…
Adam B. Murphy, MD, MBA, MSCI is Assistant Professor in the Department of Urology & Preventive Medicine at Northwestern University. He is Principal Investigator of a new study seeking to develop a genetic panel specifically to predict lethal prostate cancer…
A new drug approved by the Food and Drug Administration (FDA) is expected to immediately affect the treatment of some men with prostate cancer. In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at…
